Cargando…
Network Meta-Analysis of Randomized Controlled Trials: Efficacy and Safety of UDCA-Based Therapies in Primary Biliary Cirrhosis
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compar...
Autores principales: | Zhu, Gui-Qi, Shi, Ke-Qing, Huang, Sha, Huang, Gui-Qian, Lin, Yi-Qian, Zhou, Zhi-Rui, Braddock, Martin, Chen, Yong-Ping, Zheng, Ming-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602497/ https://www.ncbi.nlm.nih.gov/pubmed/25789951 http://dx.doi.org/10.1097/MD.0000000000000609 |
Ejemplares similares
-
A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis
por: Ma, Hong, et al.
Publicado: (2016) -
A network meta-analysis of the efficacy and side effects of udca-based therapies for primary sclerosing cholangitis
por: Zhu, Gui-Qi, et al.
Publicado: (2015) -
Nonalcoholic Fatty Liver Disease: A Negative Risk Factor for Colorectal Cancer Prognosis
por: You, Jie, et al.
Publicado: (2015) -
Case–Control Study on Prednisolone Combined With Ursodeoxycholic Acid and Azathioprine in Pure Primary Biliary Cirrhosis With High Levels of Immunoglobulin G and Transaminases: Efficacy and Safety Analysis
por: Fang, Yu-Qing, et al.
Publicado: (2014) -
Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis
por: Zhu, Gui-Qi, et al.
Publicado: (2015)